MS
KYMR icon

Maven Securities’s Kymera Therapeutics KYMR Stock Holding History

Maven Securities’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,000
Closed -$1.17M – 489
2025
Q4 		$1.17M Buy
+15,000
New +$1.01M 0.03% 376
2025
Q3 		– Sell
-50,000
Closed -$2.18M – 663
2025
Q2 		$2.18M Buy
+50,000
New +$1.72M 0.05% 301
2020
Q4 		– Sell
-7,143
Closed -$226K – 718
2020
Q3 		$226K Buy
+7,143
New +$218K 0.02% 534

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Maven Securities's KYMR Position: Q1 2026 in Review

Maven Securities sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 15,000 shares — an estimated $1.17M sold.

Maven Securities first reported a position in KYMR in Q3 2020 and held it in 3 quarters. The position peaked at $2.18M in Q2 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Maven Securities reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Maven Securities sold 15,000 Kymera Therapeutics shares in Q1 2026, an estimated $1.17M.
  • Maven Securities first reported a position in Kymera Therapeutics in Q3 2020 and held it in 3 quarters.
  • Maven Securities's Kymera Therapeutics position peaked at $2.18M in Q2 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.